Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Jazz to buy cannabinoid company GW for $7.2 billion

by Megha Satyanarayana
February 6, 2021 | A version of this story appeared in Volume 99, Issue 5

 

Jazz Pharmaceuticals is buying GW Pharmaceuticals for $7.2 billion to expand its neurological disease portfolio to include epilepsy and psychiatry. GW specializes in cannabinoid-based therapeutics, including the US Food and Drug Administration–approved Epidolex for seizures. Jazz has several approved treatments for cancer and sleep disorders. The purchase is expected to be finalized in the second quarter.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.